Omega-3 PUFAs have shown promise as supplemental agents in the process of controlling hypertension and prevention of cardiovascular disease by a variety of complementary vasoactive pathways. Nonetheless, the heterogeneity of the studies does not allow conclusive findings on the best dosing strategies. Standardized hypertension-oriented large-scale randomized controlled trials conducted in the future are justified to improve clinical practice.
Jawhar et al. (Mon,) studied this question.